SAB Biotherapeutics

SAB Biotherapeutics

SAB Biotherapeutics emerged from the University of South Dakota and SAB Capra, a predecessor entity that used genetically engineered goats, shifting to cattle in 2014 under co-founder Eddie Sullivan. The company incorporated in South Dakota and built a purpose-designed livestock facility to house its proprietary transgenic herd. Sullivan, a reproductive physiologist by training, serves as president and CEO; the firm has been his primary vehicle for translating academic research into a publicly traded platform company. SAB operates a single-platform model organized entirely around the DiversitAb system, which uses genetically modified cattle to generate high volumes of fully human polyclonal antibodies without requiring human donors. The firm targets infectious disease and autoimmune indications, with named programs advancing through Phase 2 clinical trials for seasonal influenza and Phase 1 for type 1 diabetes. Its executed contract with the U.S. Department of Defense and BARDA, funded at up to $219 million, positioned DiversitAb as a candidate for rapid medical countermeasure development — including an investigational therapeutic for Middle East Respiratory Syndrome. SAB maintains a North American operational footprint centered on its Sioux Falls headquarters and research facilities in South Dakota. The company reports its platform can produce hundreds of treatment doses from a single animal, compressing the timeline from pathogen identification to clinical material to under three months. In November 2023, SAB received authorization to conduct a Phase 1 clinical trial in Australia for its type 1 diabetes candidate, SAB-142, expanding its pipeline into autoimmune disease (per the company, November 2023). The firm does not operate a family office vehicle or adjacent philanthropic foundation, allocating capital through public equity raises, government contracts, and structured equity facilities to advance its clinical pipeline. SAB's structural differentiator is the copy-exact biological production system embedded in its transgenic cows. While traditional antibody manufacturing relies on bioreactors or convalescent plasma, SAB owns the entire stack — genetic engineering, herd management, plasma collection, and purification — and generates polyclonal antibodies that target multiple epitopes on a pathogen, a feature monoclonal antibodies cannot replicate. This hands control of both surge capacity and yield curve to a single operator, creating a sourcing model that defense agencies have funded explicitly for pandemic preparedness.